The global demand for Human Hepatitis B ImmunoglobulinMarket is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2020 with a CAGR of XX% under the study period of 2019- 2026.
Human Hepatitis B Immunoglobulin (HBIG) is produced from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. HBIG are used to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may cause to hepatocellular carcinoma which is a type of liver cancer. So, the hepatitis-B vaccines are cancer-preventing vaccines. As per Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine.
Rising adoption of HBIG due to it provides immediate, short-term protection against hepatitis B infection and prevent illness are the key factors that drive the market demand. In addition to this, high rates of hepatitis B infection, administration to pregnant women during their third trimester of pregnancy for the prevention of mother‐to‐child transmission of HBV infection,vaccination of newborns for reduction of the risk of infection, and reduction in liver cancer is expected to propel the market growth during the forecast period. Though, emerging technology during preparation of HBIG in medical sector is anticipated to create potential opportunities for Human HBIG market in the coming year. However, risk of thrombosis (blood clots) may hamper the market growth.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each type and applicationsegment in the global market of human hepatitisB immunoglobulin.
The entire human hepatitis B immunoglobulin market has been sub-categorized into type and application. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Positive infants born with Hepatitis B Surface Antigen (HBsAg)
- Unexpected crowd of Hepatitis B infection
- Close contacts of patients with Hepatitis B and it’s virus carriers
This section covers regional segmentation which accentuates on current and future demand for human hepatitis Bimmunoglobulin market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Human Hepatitis B Immunoglobulin Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the human hepatitis B immunoglobulinmarket include Grifols, Hualan Biological, Boya Bio-pharmaceutical, Shanghai Institute of Biological, Shanghai RAAS, Sichuan YuandaShuyang, Tiantan Biologic, Octapharma, CSL, China, Biologic, Bayer,Baxter, and Shuanglin Bio-pharmacy. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers& acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.